Analysis restricted to only MLH1-associated cancers from both groups showed similarly high cMS mutation frequency between incident and prevalent cancers (median 0.34 in incident vs. 0.33 in prevalent tumors, p = 0.8721, Supplementary Figure S2). This evidence concerns the gene MLH1 and cancer.